Tin tức & Cập nhật

Oral, transdermal hormone therapies equally preserve bone health in premature ovarian insufficiency

Hormone therapy, whether administered orally or applied transdermally, helps maintain bone mineral density in women with premature ovarian insufficiency, according to a single-centre retrospective study.

Point-of-care testing detects RTIs faster than ever

Respiratory tract infections (RTIs) have been on the rise post-COVID-19 pandemic.

Due to high patient volumes, delayed clinic presentations, and prolonged lead times for PCR testing in the laboratory, doctors need a rapid and accurate diagnostic tool to help improve in-clinic patient workflow.

CYP2C19 tied to voriconazole-related adverse reactions in kids

Carriers of the CYP2C19 allele are at greater risk of voriconazole-induced thrombocytopenia and cholestasis, reports a Japan study.

Nerandomilast safe, effective in autoimmune disease-related PPF

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.

Vancomycin 50-mg/kg dosage helps achieve target AUCf24h

An empirical dosage of approximately 50 mg/kg on the first day of vancomycin therapy is needed to achieve an area under the concentration-time curve (AUC) in the first 24 h (AUCf24h), suggests a study while noting the use of two-point sampling in Bayesian estimations to improve accuracy.

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

Treatment with ambroxol in patients with Parkinson’s disease dementia (PDD) is safe and well tolerated but falls short of improving cognition, according to a single-centre phase II study.

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

First-line nurulimab and prolgolimab combination therapy demonstrated superior efficacy compared with prolgolimab monotherapy in patients with unresectable or metastatic melanoma, according to the OCTAVA trial presented at AACR 2025.